Johnson & Johnson presents clinical data for TECNIS PureSee lens at ASCRS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
April 10, 2026 8:00 AM EDTRobust clinical data, spans two major studies across U.S., Europe and Asia Pacific
Data reveals TECNIS PureSee IOL achieved exceptional distance and intermediate vision, low bothersome visual symptoms, high tolerance to post-op refractive errors
High patient satisfaction results with TECNIS PureSee IOL
JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) will present data from two major studies supporting the performance of its recently... More
